A Novel Therapeutic Approach in the Treatment of Patients with Non Cancerous Nociceptive Persistent Pain Associated with Depression by Investigating a Combination of Anti Depressant and NSAID in a Newly Designed Rodent Model

Abstract

Osteoarthritis was identified to be the most common non-cancerous nociceptive persistent pain associated with depression. It was reported to have considerable social impact and in addition lacks appropriate therapy. Therefore the current research work was intended to identify a novel therapeutic approach for this indication. Any novel therapy demands strong basic research. To do basic research, animal model play a vital role. Currently, to our knowledge there is no animal model of OA and other non-cancerous nociceptive persistent pain that express both chronic pain and depression. In order to identify a suitable animal model, existing animal models of OA was analyzed for the suitability of developing it further as a new model that will express both chronic pain and depression. MIA induced rat knee OA was identified to be the most commonly studied OA animal model that was reported to exhibit symptoms characteristic of human OA. Therefore, MIA induced OA model was selected to research further. Interestingly, our research has shown that MIA induced knee OA in rats exhibit both chronic pain and depression. Similar to previous reports, the results of current study has shown that chronic OA exhibits both nociceptive (initial) and neuropathic pain (later stage). This model, therefore, would be helpful for evaluating drugs alone and in combination with multi-pronged action on persistant pain (nociceptive and neuropathic) and pain induced depression associated with OA. newlineUsing this model, novel therapy based on translational medicine approach involving the combination of NSAID + Antidepressants were researched. In addition, the current research highlights the potential of Duloxetine + Dexibuprofen as the novel therapy in the treatment of chronic OA. Both the new animal model and the highlighted potential therapy were critically important for global research community working on chronic nociceptive pain and indirectly to millions of suffering OA patients looking for most effective therapy.